ISSN 2149-2263 | E-ISSN 2149-2271 Home      
 
Volume : 24 Issue : 2
Current Issue Archive Popular Article Ahead of Print

 
Presence of a D8/17 B lymphocyte marker and HLA-DR subgroups in patients with rheumatic heart disease [Anatol J Cardiol]
Anatol J Cardiol. 2011; 11(4): 314-318 | DOI: 10.5152/akd.2011.082  

Presence of a D8/17 B lymphocyte marker and HLA-DR subgroups in patients with rheumatic heart disease

Cemşit Karakurt1, Can Celiloğlu2, Ünsal Özgen3, Elif Yeşilada4, Saim Yoloğlu5, John Zabriskie6, Gülendam Koçak1
1From Department of Pediatric Cardiology, Faculty of Medicine, İnönü University, Malatya-Turkey
2From Department of, Pediatrics Faculty of Medicine, İnönü University, Malatya-Turkey
3From Department of Pediatric Hematology Faculty of Medicine, İnönü University, Malatya-Turkey
4From Department of Molecular Biology and Genetics, Faculty of Medicine, İnönü University, Malatya-Turkey
5From Department of Biostatistics, Faculty of Medicine, İnönü University, Malatya-Turkey
6Department of Clinical Microbiology and Immunology, Rockefeller University, New York-USA
7From Department of Pediatric Cardiology, Faculty of Medicine, İnönü University, Malatya-Turkey

Objective: The aim of our study was to investigate the association of HLA antigens and a non-HLA protein D8/17 with rheumatic heart disease and its pattern of cardiac involvement. Methods: This cross- sectional observational study included 35 children and 12 adult patients who have rheumatic heart disease and 35 healthy children and 12 healthy adult controls. After physical examination, all patients and control group members were evaluated with 2D and color-coded echocardiography. B- lymphocyte D8/17 expression was tested by a flow cytometry assay. HLA genotyping was performed using polymerase chain reaction sequence-specific primers. In statistical analysis, Chi-square, unpaired t and Mann-Whitney U tests were used for comparison groups. Results: The percentage of the D8/17-expressing B lymphocytes of the patient group was significantly higher than of the control group (77.3±15.6% vs. 67.7±20.0%, p=0.013). When compared with the control group, the HLA DRB5 (38.6% vs. 13.6%, p=0.007) and HLA DRB1*15 (31.8% vs. 9.0%, p=0.008) expression levels of the patient group were significantly higher and the DRB4 expression of the patient group was significantly lower (29.5% vs. 50.0%, p=0.049). Conclusion: Our findings support the association between HLA Class 2 subgroups and rheumatic heart disease, and an association between D8/17 expression and rheumatic heart disease. Further studies including higher number of patients and control group members should be performed for the confirmation of our results.

Keywords: Rheumatic heart disease, human leukocyte antigen DR subgroups, beta-lymphocyte D8/17 antigen, flow cytometry


Cemşit Karakurt, Can Celiloğlu, Ünsal Özgen, Elif Yeşilada, Saim Yoloğlu, John Zabriskie, Gülendam Koçak. Presence of a D8/17 B lymphocyte marker and HLA-DR subgroups in patients with rheumatic heart disease. Anatol J Cardiol. 2011; 11(4): 314-318


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share


Similar articles
PubMed
Google Scholar




 
 
KARE Publishing | Copyright © 2019 Turkish Society of Cardiology